| 0.8408 0.04 (5.02%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.39 | 1-year : | 1.79 |
| Resists | First : | 1.19 | Second : | 1.53 |
| Pivot price | 1.06  |
|||
| Supports | First : | 0.63 | Second : | 0.52 |
| MAs | MA(5) : | 0.96 |
MA(20) : | 1.12 |
| MA(100) : | 1.26 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 23.3  |
D(3) : | 16.9 |
| RSI | RSI(14): 34.5 |
|||
| 52-week | High : | 4.42 | Low : | 0.63 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CTXR ] has closed below the lower bollinger band by 0.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ CTXR ] is to continue within current trading range. Bollinger Bands are 1.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.86 - 0.87 | 0.87 - 0.87 |
| Low: | 0.79 - 0.79 | 0.79 - 0.8 |
| Close: | 0.83 - 0.84 | 0.84 - 0.85 |
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Wed, 24 Dec 2025
CITIUS PHARMACEUTICALS Q4 2025 Earnings Preview: Recent $CTXR Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Wed, 24 Dec 2025
Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why - Benzinga
Tue, 23 Dec 2025
Citius Pharmaceuticals (CTXR) Reports Wider Annual Loss - GuruFocus
Tue, 23 Dec 2025
Citius Pharmaceuticals (CTXR) Reports Earnings Miss with Increas - GuruFocus
Tue, 23 Dec 2025
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - PR Newswire
Tue, 23 Dec 2025
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - WV News
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 18 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 13 (%) |
| Shares Short | 2,400 (K) |
| Shares Short P.Month | 2,580 (K) |
| EPS | -4.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.48 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.9 % |
| Return on Equity (ttm) | -54.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | 18 (M) |
| PE Ratio | -0.18 |
| PEG Ratio | 0 |
| Price to Book value | 0.18 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|